This clinical study tests a new cancer treatment called **MDNA11**. It's a special form of a protein called interleukin-2 (IL-2) that helps the body's immune system fight cancer. The study is in its early stages (Phase 1/2) and aims to see if **MDNA11** is safe and works well, both by itself and with another medicine called a *checkpoint inhibitor*. The study involves up to 115 patients with advanced solid tumors at 30 clinical sites.
Key points to consider:
- **Visits**: Tumor checks every 8 weeks with CT/MRI scans.
- **Duration**: You can stay in the study as long as the treatment is helping or until you choose to stop.
- **Eligibility**: Must be 18+, with certain health conditions and agree to use birth control if applicable.
Participants will have regular health checks and can leave the study anytime. The treatment involves MDNA11 alone or with pembrolizumab, and may include risks like side effects from the drugs. It's important to discuss the risks and benefits with your doctor before joining.
How understandable was the trial content above?
Hard to understand
Easy to understand